Eagle Pharma Gets FDA Qualified Infectious Disease Product (QIDP) And Fast-Track Designation For CAL02, Providing Five-Year Exclusivity Extension
Portfolio Pulse from Benzinga Newsdesk
Eagle Pharmaceuticals has received FDA Qualified Infectious Disease Product (QIDP) and Fast-Track designation for CAL02, potentially extending exclusivity for five years. The company is also working on developing the patent estate to protect the intellectual property of this first-in-class therapy.
June 14, 2023 | 10:51 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eagle Pharmaceuticals' stock may benefit from the FDA QIDP and Fast-Track designation for CAL02, potentially extending exclusivity for five years.
The FDA QIDP and Fast-Track designation for CAL02 is a positive development for Eagle Pharmaceuticals. This could lead to a potential five-year exclusivity extension, which would protect the company's intellectual property and potentially increase revenue. As a result, this news is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100